Abstract
Bicyclol, a novel synthetic anti-hepatitis drug, has a potent hepatocyte-protective effect and a mild anti-hepatitis virus function. However, its pharmaceutical effects and mechanism are still unclear. In the present study, we found that bicyclol pre-treatment could attenuate the production of the inflammatory cytokines (TNF-alpha and IL-18) and chemokines (MCP-1, MIP-1 alpha and Rantes) and inhibit the activation of the p65-NF-kappaB and MAPK signaling pathways in CpG-ODN 2006-stimulated L02 hepatocytes in a dose-dependent manner. Collectively, these results suggest that bicyclol could exert its hepatocyte-protective effect through attenuating CpG-ODN 2006-stimulated inflammatory responses in L02 hepatocytes, which might be associated with the activations of NF-kappaB and MAPK pathways.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Biphenyl Compounds / pharmacology*
-
Blotting, Western
-
Chemokines / biosynthesis*
-
CpG Islands
-
Cytokines / biosynthesis*
-
DNA / pharmacology*
-
DNA, Viral / pharmacology
-
Enzyme Activation / drug effects
-
Enzyme-Linked Immunosorbent Assay
-
Flow Cytometry
-
Fluorescent Antibody Technique
-
Hepatocytes / drug effects
-
Hepatocytes / enzymology
-
Hepatocytes / metabolism*
-
Humans
-
Inflammation / metabolism*
-
Nuclear Proteins / biosynthesis
-
Nuclear Proteins / isolation & purification
-
Signal Transduction / drug effects
-
Stimulation, Chemical
-
Toll-Like Receptor 9 / physiology
-
Transcription Factor RelA / antagonists & inhibitors*
-
Transcription Factor RelA / metabolism*
-
p38 Mitogen-Activated Protein Kinases / antagonists & inhibitors*
-
p38 Mitogen-Activated Protein Kinases / metabolism*
Substances
-
Biphenyl Compounds
-
Chemokines
-
Cytokines
-
DNA, Viral
-
Nuclear Proteins
-
TLR9 protein, human
-
Toll-Like Receptor 9
-
Transcription Factor RelA
-
DNA
-
bicyclol
-
p38 Mitogen-Activated Protein Kinases